MCM
COCP icon

MAI Capital Management’s Cocrystal Pharma COCP Stock Holding History

MAI Capital Management’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-237
Closed -$240 – 2594
2026
Q1 		$240 Hold
237
– – ﹤0.01% 4580
2025
Q4 		$233 Hold
237
– – ﹤0.01% 4010
2025
Q3 		$297 Hold
237
– – ﹤0.01% 3676
2025
Q2 		$354 Hold
237
– – ﹤0.01% 3811
2025
Q1 		$337 Hold
237
– – ﹤0.01% 3266
2024
Q4 		$479 Buy
+237
New +$474 ﹤0.01% 3301

Other funds holding COCP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MAI Capital Management's COCP Position: Q2 2026 in Review

MAI Capital Management sold out of Cocrystal Pharma (COCP) in Q2 2026, closing a stake of 237 shares — an estimated $240 sold.

MAI Capital Management first reported a position in COCP in Q4 2024 and held it in 6 quarters. The position peaked at $479 in Q4 2024. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

  • MAI Capital Management reported no remaining Cocrystal Pharma position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 237 Cocrystal Pharma shares in Q2 2026, an estimated $240.
  • MAI Capital Management first reported a position in Cocrystal Pharma in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Cocrystal Pharma position peaked at $479 in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.